|
EUS-Gallbladder vs CDS as First Line in MBDO- Palliative (CARPEGIEM Trial)
RECRUITINGN/ASponsored by Hospital Universitari de Bellvitge
Actively Recruiting
PhaseN/A
SponsorHospital Universitari de Bellvitge
Started2024-10-18
Est. completion2026-10
Eligibility
Age18 Years – 100 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT06375967
Summary
The aim of the study is to evaluate technical, clinical and safety outcomes of lumen-apposing metal stent (LAMS) with a coaxial double-pigtail plastic stent (DPS) in EUS-guided choledochoduodenostomies vs cholcystogastrostomy for the management of malignant biliary obstruction in palliative patients.
Eligibility
Age: 18 Years – 100 YearsHealthy volunteers accepted
Inclusion Criteria: * Malignant distal biliary obstruction diagnosed in patient considered PALIATIVE with biliary drainage indication. * Consensual malignancy by a bilio-pancreatic multidisciplinar committe (histological confirmation is not mandatory) * Patient capable of understanding and/or singning the informed consent. * Patient who understands the type of study and will comply with all follow-up tests throughout its duration Exclusion Criteria: * Pregnancy or lactation. * Severe coagulation disorder: INR \> 1.5 non correctable with plasma administration and/or platelet count \< 50.000/mm3. * Previous cholecistectomy or gallblader perforation. * Tumoral obstruction of cystic duct. * Multiple liver metastases affecting more than 30% of the liver parenchyma * Distal malignant biliary strictures in patients considered resectable or borderline. * Benign or uncertain etiology of biliary strictures or strictures located proximally or in close proximity to the hilum. * Patients with prior biliary stents or other biliary drainages (e.g., PTCD). * Altered intestinal anatomy due to prior surgery that prevents or hinders papillary access \_\_\_\_\_\_\_\_\_\_\_\_\_\_ (e.g., gastric bypass, Billroth II, duodenal switch, Roux-en-Y). * Gastric outlet obstruction. * Situations that do not allow for upper gastrointestinal endoscopy (e.g., esophageal stricture). * Patients with functional diversity, who lack the capacity to understand the nature and potential consequences of the study, except when a legal representative is available. * Patients incapable of maintaining follow-up appointments (lack of adherence). * Lack of informed consent.
Conditions4
Biliary Tract NeoplasmsCancerMalignant Biliary ObstructionPancreatic Cancer Non-resectable
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhaseN/A
SponsorHospital Universitari de Bellvitge
Started2024-10-18
Est. completion2026-10
Eligibility
Age18 Years – 100 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT06375967